Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 10.2% in November

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,940,000 shares, an increase of 10.2% from the October 31st total of 1,760,000 shares. Currently, 17.2% of the company’s shares are short sold. Based on an average daily volume of 275,500 shares, the short-interest ratio is presently 7.0 days.

Jasper Therapeutics Stock Performance

JSPR stock opened at $23.97 on Tuesday. The company has a market capitalization of $359.57 million, a price-to-earnings ratio of -5.06 and a beta of 2.19. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01. The stock has a fifty day moving average of $20.28 and a 200-day moving average of $20.92.

Institutional Trading of Jasper Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in shares of Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares during the period. Wolff Wiese Magana LLC purchased a new position in Jasper Therapeutics during the 3rd quarter valued at about $59,000. MetLife Investment Management LLC increased its stake in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Jasper Therapeutics in the 3rd quarter worth approximately $251,000. Finally, Rhumbline Advisers purchased a new stake in shares of Jasper Therapeutics in the 2nd quarter worth approximately $300,000. Institutional investors own 79.85% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a report on Thursday, October 24th. Royal Bank of Canada reduced their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Evercore ISI reissued an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research report on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Finally, JMP Securities restated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics has an average rating of “Buy” and an average price target of $74.86.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.